Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation (Tables)

Share-based compensation (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:


	Three months ended October 31,
	2012		2011

Cost of clinical laboratory services	$	2	$	2
Research and development		1		3
Selling, general and administrative		139		208

	$	142	$	213

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the activity relating to the Company’s stock option plans for the three month period ended October 31, 2012 is as follows:


	Options			Weighted Average Exercise Price		Aggregate Intrinsic Value

Outstanding at July 31, 2012		736,490		$	14.50	$	—

Exercised		—			—
Cancelled		(50,638	)	$	11.25

Outstanding and exercisable at end of period		685,852		$	14.74	$	—

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the activity pursuant to the Company’s restricted stock awards for the three months ended October 31, 2012 is as follows:


	Awards			Weighted Average Award Price

Unvested at July 31, 2012		257,583		$	3.58
Awarded		30,000		$	1.52
Vested		(500	)	$	(3.93	)
Forfeited		(3,292	)	$	(5.13	)

Unvested at end of period		283,791		$	3.34

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details